Physician profile
Amanda Garner
NPI 1851812531
$2,818.33
in general payments reported to CMS, 2019-2025
39 companies · $1,761 in 2025
The $1,761 reported for 2025 was more than what 94% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $30.90 · 2024: $1,027 · 2025: $1,761.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,503 · Education: $284.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,503.45 |
| Education | $283.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $328.62 | 2024-2025 | Lynparza, Tagrisso, Enhertu |
| Takeda Pharmaceuticals U.S.A., INC. | $265.04 | 2024-2025 | Fruzaqla, Iclusig, Ninlaro |
| Exelixis INC. | $179.62 | 2024-2025 | Cabometyx |
| Genentech USA, INC. | $150.73 | 2024-2025 | Venclexta, Itovebi, Polivy |
| Novartis Pharmaceuticals Corporation | $142.21 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $129.07 | 2024-2025 | Keytruda, Welireg, Reblozyl |
| Daiichi Sankyo INC. | $120.95 | 2024-2025 | Enhertu |
| Genzyme Corporation | $112.48 | 2024-2025 | |
| Glaxosmithkline, LLC. | $102.36 | 2024-2025 | Ojjaara |
| Seagen INC. | $99.00 | 2024 | |
| Pfizer INC. | $90.99 | 2025 | |
| Abbvie INC. | $84.26 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $83.77 | 2024-2025 | |
| Sobi, INC | $77.82 | 2024-2025 | |
| Janssen Biotech, INC. | $74.35 | 2024-2025 | Talvey, Darzalex, Tecvayli |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Garner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.